Novo Nordisk A/S Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novo Nordisk A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View analyst ratings for Novo Nordisk A/S or view top-rated stocks.

Wall Street analysts have given Novo Nordisk A/S a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novo Nordisk A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Novo Nordisk A/S.

Novo Nordisk A/S (NYSE:NVO) issued its earnings results on Tuesday, February, 2nd. The company reported $4.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.60 by $3.41. Novo Nordisk A/S had a net margin of 32.65% and a trailing twelve-month return on equity of 71.46%.
View Novo Nordisk A/S's earnings history.

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVO shares have increased by 20.2% and is now trading at $69.61.
View which stocks have been most impacted by COVID-19.

Novo Nordisk A/S announced a semi-annual dividend on Tuesday, February 23rd. Stockholders of record on Monday, March 29th will be paid a dividend of $0.9494 per share on Wednesday, April 7th. This represents a dividend yield of 1.3%. The ex-dividend date is Friday, March 26th. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.78.
View Novo Nordisk A/S's dividend history.

Novo Nordisk A/S pays an annual dividend of $0.74 per share and currently has a dividend yield of 1.04%. Novo Nordisk A/S does not yet have a strock track record of dividend growth. The dividend payout ratio of Novo Nordisk A/S is 30.08%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 25.00% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.

Novo Nordisk A/S issued an update on its FY 2021 Pre-Market earnings guidance on Wednesday, February, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $21.354-22.167 billion, compared to the consensus revenue estimate of $21.76 billion.

10 analysts have issued 12-month target prices for Novo Nordisk A/S's stock. Their forecasts range from $72.00 to $72.00. On average, they expect Novo Nordisk A/S's share price to reach $72.00 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts' price targets for Novo Nordisk A/S or view top-rated stocks among Wall Street analysts.

372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche (RHHBY), Abbott Laboratories (ABT), Eli Lilly and (LLY), Novartis (NVS), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Sanofi (SNY), CSL (CSLLY), GlaxoSmithKline (GSK), Zoetis (ZTS) and Bayer Aktiengesellschaft (BAYRY).
View all of NVO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.14%), Fisher Asset Management LLC (0.67%), Folketrygdfondet (0.24%), Fayez Sarofim & Co (0.21%), Everett Harris & Co. CA (0.14%) and Clearbridge Investments LLC (0.11%).
View institutional ownership trends for Novo Nordisk A/S.

NVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Eaton Vance Management, Eaton Vance Management, Jennison Associates LLC, Credit Suisse AG, BlackRock Inc., Alliancebernstein L.P., and Calamos Advisors LLC.
View insider buying and selling activity for Novo Nordisk A/S or view top insider-selling stocks.

NVO stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Amundi Pioneer Asset Management Inc., Clearbridge Investments LLC, Folketrygdfondet, Fisher Asset Management LLC, Aperio Group LLC, Creative Planning, and Penbrook Management LLC.
View insider buying and selling activity for Novo Nordisk A/S or or view top insider-buying stocks.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVO stock can currently be purchased for approximately $69.61.

Novo Nordisk A/S has a market capitalization of $163.92 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis.

Novo Nordisk A/S employs 44,326 workers across the globe.

The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., Calibrium, Churchill Stateside Solar Fund XIV LLC, Corvidia, Emisphere Technologies, MB2 LLC, NNE A/S, Novo Investment Pte Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk B.V., Novo Nordisk Biopharm Limited, Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comercio Produtos Farmaceuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungaria Kft., Novo Nordisk Inc., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZ-LLC, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Scandinavia AB, Novo Nordisk Scandinavia AS, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representacion C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, and Ziylo.

Novo Nordisk A/S was founded in 1923.

The official website for Novo Nordisk A/S is www.novonordisk.com.

Novo Nordisk A/S is headquartered at Novo Alle, Bagsvaerd G7, 2880.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]